Compounds > 2'-deoxy-4'-thiocytidine

Page last updated: 2024-11-12

2'-deoxy-4'-thiocytidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2'-deoxy-4'-thiocytidine: RN & structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	10037425
CHEMBL ID	1169490
SCHEMBL ID	2401955
MeSH ID	M0191847

Synonyms (16)

Synonym
2-dtcd
CHEMBL1169490
2'-deoxy-4'-thiocytidine
tdcyd
4'-thio-2'-deoxycytidine, (-)-
4'-thio-2'-deoxycytidine
nsc-764276
unii-l76o0m313f
cytidine, 2'-deoxy-4'-thio-
l76o0m313f ,
134111-30-1
SCHEMBL2401955
1-(2-deoxy-4-thio-beta-d-ribofuranosyl)cytosine
MOMUJZRKXYLWMH-SHYZEUOFSA-N
Q27282802
4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidin-2-one

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay ID	Title	Year	Journal	Article
AID543554	Antiviral activity against Vaccinia virus Copenhagen infected in HFF assessed as reduction of plaque formation at 100 uM after 3 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID543555	Antiviral activity against Vaccinia virus WR infected in HFF assessed as reduction of plaque formation at 100 uM after 3 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID543556	Antiviral activity against Cowpox virus Brighton infected in HFF assessed as reduction of plaque formation at 100 uM after 3 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID543557	Antiviral activity against wild type Vaccinia virus infected in HFF assessed as reduction of plaque formation after 3 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
AID79241	The concentration required to produce a 50% inhibition of clone formation in human epidermoid carcinoma H-Ep-2 cells	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and biological activity of 2'-deoxy-4'-thio pyrimidine nucleosides.
AID98517	The concentration required to produce a 50% reduction in the rate of cell proliferation in murine leukemia L1210 cells	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and biological activity of 2'-deoxy-4'-thio pyrimidine nucleosides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (25.00)	18.2507
2000's	3 (37.50)	29.6817
2010's	2 (25.00)	24.3611
2020's	1 (12.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.42 (24.57)
Research Supply Index	2.20 (2.92)
Research Growth Index	4.62 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.42)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
thymidine [no description available]	1.97	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
idoxuridine [no description available]	2.05	1	0	organoiodine compound; pyrimidine 2'-deoxyribonucleoside	antiviral drug; DNA synthesis inhibitor
cytarabine [no description available]	2	1	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
xylitol xylooligosaccharide: structure in first source. pentitol : An alditol obtained by reduction of any pentose.. xylooligosaccharide : An oligosaccharide comprised of xylose residues.	2	1	0
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	3.89	2	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
deoxycytidine [no description available]	5.24	8	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
deoxyuridine [no description available]	1.97	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	2.05	1	0	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
2'-deoxycytidine 5'-triphosphate 2'-deoxycytidine 5'-triphosphate: RN given refers to unlabeled parent cpd	2	1	0	2'-deoxycytidine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-triphosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
4'-thiothymidine [no description available]	2.41	2	0
thiouridine Thiouridine: A photoactivable URIDINE analog that is used as an affinity label.. 4-thiouridine : A thiouridine in which the oxygen replaced by sulfur is that at C-4.	1.97	1	0	nucleoside analogue; thiouridine	affinity label; antimetabolite
4'-thiothymidine 4'-thiothymidine: RN & structure given in first source	1.97	1	0
st-246 tecovirimat: A potent and specific inhibitor of orthopoxvirus replication. It is used for the treatment of SMALLPOX and other orthopoxvirus infections, including MONKEYPOX under expanded access investigational new drug protocol (https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html).	2.05	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Carcinoma, Epidermoid [description not available]	0	1.97	1	0
Leukemia L 1210 [description not available]	0	1.97	1	0
Leukemia, Lymphocytic, T Cell [description not available]	0	1.97	1	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	0	1.97	1	0
Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.	0	1.97	1	0
Leukemia, T-Cell A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.	0	1.97	1	0
Vaccinia The cutaneous and occasional systemic reactions associated with vaccination using smallpox (variola) vaccine.	0	2.05	1	0
Cow Pox [description not available]	0	2.05	1	0
Infections, Poxviridae [description not available]	0	2.05	1	0
Benign Neoplasms [description not available]	0	2.31	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1	4.31	1	0
Experimental Neoplasms [description not available]	0	4.96	4	0